

Reminder: Quantity Limit Restrictions for Anti-Obesity Preparations

July 24, 2024

Background

The purpose of this alert is to remind pharmacy providers and prescribers of the Quantity Limit (QL) restrictions for Wegovy® (semaglutide) and Saxenda® (liraglutide).

What Pharmacy Providers and Prescribers Need to Know

Wegovy (semaglutide) and Saxenda (liraglutide) are restricted to a maximum quantity of one carton per dispensing and one dispensing every 28 days.

Note: One carton of Wegovy (semaglutide) contains four single-dose pen injectors and Saxenda (liraglutide) contains five prefilled pens. Claims submitted to Medi-Cal Rx that meet the QL restrictions for Wegovy (semaglutide) and Saxenda (liraglutide) should be submitted as follows:

Drug	Quantity/Days' Supply
Wegovy (Semaglutide)	
0.25 mg/0.5 ml	2 ml/28 days
0.5 mg/0.5 ml	2 ml/28 days
1 mg/0.5 ml	2 ml/28 days
1.7 mg/0.75 ml	3 ml/28 days
2.4 mg/0.75 ml	3 ml/28 days
Saxenda (Liraglutide)	
18 mg/3 ml	15 ml/28 days

Note: Claims submitted in which either the quantity or days' supply exceeds the values mentioned above will deny with **Reject Code 76 – Plan Limitations Exceeded**.

What Pharmacy Providers and Prescribers Need to Do

- 1. For product-specific QLs and utilization management (UM) information, refer to the UM Type and Code I columns in the <u>Medi-Cal Rx Contract Drugs List</u>.
- 2. If resubmission of the claim to meet Code I restrictions is not appropriate, a prior authorization (PA) request is required for coverage consideration.

Reminder: Quantity Limit Restrictions for Anti-Obesity Preparations

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.